This clinical trial is focused on studying the effects of a medication called vemurafenib, also known by its code names RO5185426 and PLX4032. The study is designed for patients with certain types of cancers that have a specific genetic change known as a BRAF genomic alteration. These cancers include, but are not limited to, non-small cell lung cancer, ovarian cancer, cholangiocarcinoma (a type of bile duct cancer), thyroid cancer, prostate cancer, bladder cancer, sarcoma, gastrointestinal stromal tumors (GIST), multiple myeloma, chronic lymphocytic leukemia (CLL), and hairy cell leukemia (HCL). The purpose of the study is to explore how effective vemurafenib is when used alone to treat these cancers.

Participants in the study will receive vemurafenib in the form of film-coated tablets. The study will monitor the response of the tumors to the medication over a period of time. The main goal is to see if the tumors shrink or stop growing. The study will also look at how long the treatment works, how long patients live without the disease getting worse, and overall survival rates. Additionally, the safety of vemurafenib will be assessed to ensure it is well-tolerated by patients.

This trial is important for understanding how vemurafenib can be used to treat different types of cancers that share the BRAF genomic alteration. By focusing on this specific genetic change, the study aims to provide more targeted treatment options for patients whose cancers are not responding to standard therapies. The results could lead to new ways of managing these cancers and improving patient outcomes.